» Articles » PMID: 31335804

How Are Transgender Women Acquiring HIV? Insights from Phylogenetic Transmission Clusters in San Francisco

Overview
Journal AIDS
Date 2019 Jul 24
PMID 31335804
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: We explored potential HIV transmission typologies that involve transgender women to obtain insights on sexual and needle-sharing networks as sources of HIV infection.

Design: San Francisco residents diagnosed with HIV in care at public facilities who had available viral pol sequences from June 2001 to January 2016 were included in the analysis.

Methods: Viral sequence data were matched to the San Francisco HIV/AIDS Case Registry to obtain demographic and risk classification information. Transmission clusters with at least two cases were identified by bootstrap values at least 90% and mean pairwise genetic distances 0.025 or less substitutions per site.

Results: Transgender women represented 275 of 5200 patients; 86 were present in 70 clusters. Four typologies were hypothesized: first, transgender women in clusters with MSM; second, transgender women who inject drugs in clusters with cisgender women and men who inject drugs; third, multiple transgender women in clusters with one man; and fourth, multiple transgender women who do not inject drugs in clusters with men and cisgender women who inject drugs.

Conclusion: Transmission patterns of transgender women may stand apart from MSM epidemics. Transgender women clustered with people who inject drugs, and with men who have sex with transgender women and cisgender women. Aggregation of transgender women into the category of MSM may obscure understanding of how they acquire HIV and to whom they may transmit infection. Phylogenetic insights strengthen the case that HIV prevention programs for MSM may not be applicable to transgender women or their partners.

Citing Articles

Integrating Phylogenetic Biomarker Data and Qualitative Approaches: An example of HIV Transmission Clusters as a Sampling Frame for Semistructured Interviews and Implications for the COVID-19 Era.

Hughes S, Woods W, OKeefe K, Delgado V, Pipkin S, Scheer S J Mix Methods Res. 2024; 15(3):327-347.

PMID: 38883973 PMC: 11178346. DOI: 10.1177/15586898211012786.


HIV prevalence, engagement in care, and risk behavior among trans women, San Francisco: Evidence of recent successes and remaining challenges.

Chiu I, Leathers M, Cano D, Turner C, Trujillo D, Sicro S Int J STD AIDS. 2022; 33(12):1029-1037.

PMID: 35816424 PMC: 9607899. DOI: 10.1177/09564624221111278.


Self-Identity, Beliefs, and Behavior Among Men Who Have Sex with Transgender Women: Implications for HIV Research and Interventions.

Long J, Montano M, Sanchez H, Huerta L, Garcia D, Lama J Arch Sex Behav. 2021; 50(7):3287-3295.

PMID: 34617189 PMC: 8784120. DOI: 10.1007/s10508-021-02019-3.


Exploring HIV risk behavior and sexual/gender identities among transgender women and their sexual partners in Peru using respondent-driven sampling.

Long J, Sanchez H, Dasgupta S, Huerta L, Garcia D, Lama J AIDS Care. 2021; 34(9):1187-1195.

PMID: 34424782 PMC: 8863975. DOI: 10.1080/09540121.2021.1967855.


Non-B variants of HIV-1 in San Francisco, California.

OKeefe K, Pipkin S, Fatch R, Scheer S, Liegler T, McFarland W Infect Genet Evol. 2020; 90:104677.

PMID: 33321227 PMC: 10686190. DOI: 10.1016/j.meegid.2020.104677.


References
1.
Wilson E, Chen Y, Raad N, Raymond H, Dowling T, McFarland W . Who are the sexual partners of transgender individuals? Differences in demographic characteristics and risk behaviours of San Francisco HIV testing clients with transgender sexual partners compared with overall testers. Sex Health. 2014; 11(4):319-23. DOI: 10.1071/SH13202. View

2.
Sevelius J, Keatley J, Calma N, Arnold E . 'I am not a man': Trans-specific barriers and facilitators to PrEP acceptability among transgender women. Glob Public Health. 2016; 11(7-8):1060-75. PMC: 10204128. DOI: 10.1080/17441692.2016.1154085. View

3.
Wilson E, Jin H, Liu A, Raymond H . Knowledge, Indications and Willingness to Take Pre-Exposure Prophylaxis among Transwomen in San Francisco, 2013. PLoS One. 2015; 10(6):e0128971. PMC: 4454556. DOI: 10.1371/journal.pone.0128971. View

4.
Audelin A, Gerstoft J, Obel N, Mathiesen L, Laursen A, Pedersen C . Molecular phylogenetics of transmitted drug resistance in newly diagnosed HIV Type 1 individuals in Denmark: a nation-wide study. AIDS Res Hum Retroviruses. 2011; 27(12):1283-90. DOI: 10.1089/aid.2010.0368. View

5.
Herbst J, Jacobs E, Finlayson T, McKleroy V, Neumann M, Crepaz N . Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. AIDS Behav. 2007; 12(1):1-17. DOI: 10.1007/s10461-007-9299-3. View